LumaCyte Launches Laser Force Cytology™ Academy after Training FDA Reviewers

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--LumaCyte, a trailblazer in advanced label-free cellular bioanalytical technology and instrumentation, proudly announces the launch of the Laser Force Cytology™ Academy—an interactive library of comprehensive training courses designed to deepen understanding of LumaCyte’s transformative Laser Force Cytology™ (LFC™) optical force technology. This new offering from LumaCyte aims to empower scientists and biomanufacturers with the knowledge and skills needed to leverage the power of LFC™ cellular analytics across important process development and production laboratory workflows.

Radiance®, LumaCyte’s flagship instrument powered by LFC™, offers predictive cellular analytics for key bioprocess and manufacturing applications. By providing label-free, quantitative cell characterization, LFC™ enables scientists to monitor cellular responses in near real-time without the need for antibodies or genetic modification. These robust data insights ensure regulatory compliance and maintain potency throughout critical development and manufacturing processes.

This training initiative follows LumaCyte’s prestigious invitation to train US FDA CBER cell and gene therapy reviewers on LFC™. Such invitations are rarely extended to analytical tools companies and highlights the growing interest in advanced analytical solutions by regulators to support the increased need for novel cell-based process analytical technologies (PAT).

"Receiving the FDA’s invitation to train 120 cell and gene therapy and vaccine reviewers on Laser Force Cytology™ was an incredible honor for LumaCyte,” says Renee Hart, LumaCyte, President and Chief Business Officer. "With the CGT and vaccine markets expected to grow dramatically through 2030, it’s essential that we move beyond conventional approaches if we are to meet the treatment demands ahead. Early integration of novel real-time precision analytics will enhance both process and product understanding and accelerate ever pressing development and manufacturing timelines. The FDA’s proactive release of guidance focused on cellular products manufacturing and potency underscores the critical need for quantitative precision analytics to drive improvements in both production quality and product consistency. We are proud to support the vision of forward-thinking regulators and contribute to the advancement of bioanalytics. Real-time data insights illuminate complex development and production steps, enabling rapid scaling, reducing manufacturing failures, and ensuring successful patient treatments.”

The LumaCyte Academy comprises two modules, each designed for different learning objectives. The first module includes an introductory course on the fundamental principles of Laser Force Cytology™, allowing the broader scientific community to explore its capabilities and applications in cellular analysis and precision bioanalytics. The second module, accessible only to Radiance® users, provides a deeper dive into the instrument and technology, empowering valued customers with the skills and expertise needed to harness the full potential of Laser Force Cytology™ in their laboratory workflows and processes. Additionally, Radiance® users can now register for onsite training at LumaCyte headquarters, where LumaCyte scientific experts and data analytics engineers will provide users with hands-on training as part of the newly launched Laser Force Cytology™ Academy.

LumaCyte is dedicated to bridging the gap between cutting-edge technology and its adoption by biopharmaceutical developers and manufacturers. Through fostering a network of expert users and driving innovation, LumaCyte is advancing towards a future where Laser Force Cytology™ is integral in delivering sophisticated predictive analytics for the development and production of life saving advanced therapies.

For more information and/or access to the LumaCyte Academy, please visit www.lumacyte.com/academy.

About LumaCyte

LumaCyte, Inc. is an advanced research and bioanalytics instrumentation company that produces label-free, single cell analysis instrumentation where the use of antibody or genetic labeling is not required for cellular analysis. This revolutionary technology utilizes Laser Force Cytology™ (LFC™) to measure optical and fluidic forces within a microfluidic channel, quantitatively characterizing innate cellular responses of subtle phenotypic changes based purely on the intrinsic biophysical and biochemical properties of cells; which can be used to measure cellular changes in response to their environment or treatment. The univariate and multivariate nature of the data has enabled a host of big data strategies and cloud computing capabilities that drive advanced analytics, allowing a deeper understanding of cell based biological systems. Applications of LumaCyte's label-free platform technology include viral infectivity for vaccine development and manufacturing, cell health, activation, transfection and transduction analytics for cell and gene therapy development and production monitoring, CAR T-cell immunotherapy, iPSC differentiation, adventitious agent testing (AAT), infectious disease, and pre-clinical drug discovery, in addition to multiple applications across advanced therapy biomanufacturing for real-time quality control.

Innovate. Discover. Transform.™

Visit www.lumacyte.com for more information.